Preparation of a Preclinical Dossier to Support an Investigational New Drug (IND) Application and First-In-Human Clinical Trial

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/B978-0-12-387815-1.00012-5
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Nonclinical safety assessment : a guide to international pharmaceutical regulations

  2013cited by this paper
• Considerations Regarding Nonhuman Primate Use in Safety Assessment of Biopharmaceuticals

  2011cited by this paper
• ICH S9

  2011cited by this paper
• Comparative requirements for exploratory clinical trials -- eIND, eCTA and microdosing.

  2011cited by this paper
• Plasma protein binding and blood-free concentrations: which studies are needed to develop a drug?

  2011cited by this paper
• Functional Assays for Neurotoxicity Testing

  2011cited by this paper
• ICH guidelines: inception, revision, and implications for drug development.

  2010cited by this paper
• Predicting safety toleration of pharmaceutical chemical leads: cytotoxicity correlations to exploratory toxicity studies.

  2010cited by this paper
• Toxicology Program to Support Initiation of a Clinical Phase I Program for a New Medicine

  2010cited by this paper
• Project Management and International Regulatory Requirements and Strategies for First‐in‐Human Trials

  2010cited by this paper
• First‐in‐Human Regulatory Submissions

  2010cited by this paper
• The EMEA Guideline on First-in-Human Clinical Trials and Its Impact on Pharmaceutical Development

  2009cited by this paper
• A holistic strategy for characterizing the safety of metabolites through drug discovery and development.

  2009cited by this paper
• The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies.

  2009cited by this paper
• Immunogenicity of biologically-derived therapeutics: assessment and interpretation of nonclinical safety studies.

  2009cited by this paper
• Preclinical Safety Evaluation of Biopharmaceuticals

  2008cited by this paper
• Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412.

  2006cited by this paper
• Nonclinical Vehicle Use in Studies by Multiple Routes in Multiple Species

  2006cited by this paper
• Predictive power of preclinical studies in animals for the immunogenicity of recombinant therapeutic proteins in humans.

  2004cited by this paper
• Preclinical safety evaluation of biotechnology-derived pharmaceuticals

  2002cited by this paper
• Drug metabolites in safety testing.

  2002cited by this paper
• Commentary on: “Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse.” Psychopharmacologia (1968) 13:222257

  2002cited by this paper
• Regulatory considerations for preclinical development of anticancer drugs

  1997cited by this paper
• Screening Approaches to Neurotoxicity: A Functional Observational Battery

  1989cited by this paper
• Comprehensive observational assessment: Ia. A systematic, quantitative procedure for assessing the behavioral and physiologic state of the mouse

  1968cited by this paper

• The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States.

  2025cites this paper
• Preclinical assessments of vaginal microbicide candidate safety and efficacy.

  2015influential citation
• Análise da concentração de compostos bioativos e avaliação da toxicidade aguda in vivo dos diterpenos cafestol e caveol presentes no óleo de grãos de café verdes obtidos por extração supercrítica e por extração com fluido pressurizado

  2015cites this paper